CLINICAL_TRIALS
trial_result
· 2012-09-27
Clinical Trial Update: 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder [Phase 2]
Summary
A Phase 2 study evaluating the safety and effectiveness of AZD2066 for major depressive disorder was terminated; results were posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AstraZeneca | Conditions: Major Depressive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2012-09-27